The human microbiome has become one of the most intensely researched areas in biology, and one of the most commercially exploited. Here is a clear-eyed account of what we genuinely know, what is promising but unproven, and what is little more than marketing dressed in scientific language.
The microbiome moment
The human gut contains approximately 38 trillion microorganisms (bacteria, fungi, viruses, and archaea) collectively referred to as the gut microbiome. This microbial community, which weighs roughly 200 grams and encodes more genetic material than the human genome, is now understood to be intimately involved in digestion, immune function, neurological signalling, hormonal regulation, and metabolic processes. It is one of the most significant scientific discoveries of the past three decades, and it has been accompanied by one of the most significant waves of commercial exploitation.
The International Scientific Association for Probiotics and Prebiotics, the Cochrane Collaboration, and numerous independent researchers have spent the past decade trying to distinguish genuine microbiome science from the prolific wellness industry narrative built around it. The distinction is important, and not always obvious to the consumer navigating a probiotic yoghurt alongside a peer-reviewed journal.
What is genuinely established
The most robustly evidenced area of microbiome science concerns the gut-immune axis. Approximately 70 per cent of the body’s immune cells reside in the gut-associated lymphoid tissue, and the relationship between microbial diversity and immune regulation is now supported by substantial mechanistic and epidemiological evidence. Studies in germ-free mice, animals raised without any gut bacteria, show profound immune dysregulation, reinforcing the centrality of microbial communities to immune development.
The role of the gut microbiome in the gut-brain axis is similarly well-supported. The vagus nerve, which runs from the brainstem to the colon, provides a direct communication pathway between gut bacteria and the central nervous system. Gut bacteria produce neurotransmitters including serotonin (approximately 90 per cent of the body’s serotonin is produced in the gut), GABA, and dopamine precursors. Studies in both animal models and human populations have linked microbiome diversity to mood, anxiety, and stress responses.
Specific clinical applications have robust evidence. The use of faecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection, a potentially lethal gut infection, has an efficacy rate exceeding 90 per cent in clinical trials, and FMT is now recommended in multiple international clinical guidelines for this indication. Certain probiotic strains have good clinical evidence for irritable bowel syndrome symptom management, antibiotic-associated diarrhoea prevention, and, in preterm infants, reduction of necrotising enterocolitis risk.
‘The microbiome matters enormously. But the science does not yet support the confident claims made by the probiotic industry. These are different statements, and confusing them does everyone a disservice.’
What is promising but not yet proven
The most exciting, and the most overstated, area of microbiome research concerns its potential links to conditions well beyond the gut: obesity, Type 2 diabetes, cardiovascular disease, autism, Parkinson’s disease, depression, and multiple sclerosis have all been associated with microbiome differences in observational research. These associations are real. They do not yet establish causation, mechanism, or therapeutic implication.
The microbiome-obesity link is illustrative. Studies, including the frequently cited 2006 Nature paper showing that transferring gut bacteria from obese mice to germ-free mice induced weight gain, are intriguing but not directly applicable to human obesity intervention. Human microbiome composition is profoundly influenced by diet; separating microbiome effects from dietary effects in human studies is methodologically extremely difficult. No probiotic supplement has yet demonstrated clinically significant weight loss in rigorous human trials.
Similarly, the gut-brain axis research, while mechanistically plausible and increasingly supported by animal and small-scale human studies, has not yet produced psychobiotic interventions with strong clinical evidence for depression or anxiety management. A 2022 systematic review in The Lancet Psychiatry concluded that while the field was ‘promising,’ the existing human trials were too small, too heterogeneous, and too methodologically weak to support clinical recommendations.
What is largely hype
The commercial probiotic market, worth approximately $61 billion globally in 2023, has moved far ahead of the science on which it claims to be based. Most commercially available probiotic supplements contain strains selected for stability and manufacturability rather than clinical evidence. The probability that an orally consumed probiotic survives gastric acid, reaches the colon in viable form, and then colonises the gut of a person with an established microbial ecosystem is, for most products, low. Even where colonisation occurs, the duration of effect after supplementation stops is typically measured in days rather than weeks.
Prebiotic supplements, fibres designed to feed beneficial bacteria, have a somewhat better evidence profile, partly because they do not depend on surviving intact to the colon. But here, too, the marketing frequently outpaces the clinical evidence. The foundational insight, that dietary fibre feeds beneficial gut bacteria, was established decades before the prebiotic supplement market existed, and can be achieved for a fraction of the price through diet alone.
The dietary conclusion that is actually supported
The most consistent finding in human microbiome research, and the most actionable one, is that dietary diversity is associated with microbiome diversity, and microbiome diversity with better health outcomes. A 2021 study in Cell, involving over 1,000 participants, found that a high-fibre, plant-diverse diet was more reliably associated with microbiome health than any probiotic intervention tested.
The practical implication is straightforward, if commercially uninteresting: eating a wide variety of plant foods, including vegetables, legumes, wholegrains, fruits, nuts, and seeds, is the most evidence-based gut health intervention available. Fermented foods (kefir, yoghurt, kimchi, sauerkraut) have emerging evidence for increasing microbiome diversity and reducing inflammatory markers. These are not expensive interventions. They are, in large part, a return to the kind of dietary diversity that industrialised food systems have systematically eroded.
The microbiome matters enormously. The science around it is genuinely exciting. But it does not yet support the confident clinical claims made by the bulk of the probiotic and gut health industry. These are different statements, and the failure to make them clearly (in products, in media coverage, and in clinical settings) does everyone a disservice.